Call Today: 800-250-7280
Contact us for free information or to start a free case review.
Analysts are reassessing their earnings forecasts and are warning that at least $270 million of profits could be lost in the current financial year following the seizure of two major GlaxoSmithKline drugs by the FDA – diabetes treatment Avandamet and antidepressant Paxil CR.
The FDA said on March 4, 2005 that it was seizing batches of Avandamet and Paxil CR made at the factory due to quality problems. Some analysts believe the fact that U.S. marshals had to go in and seize supplies of the drugs suggested regulators had been pushed to wait on Glaxo to take adequate action.
Glaxo is expected to meet with the FDA within the upcoming weeks to resolve the manufacturing issues that led up to the Avandamet and Paxil withdrawal. A Glaxo spokesman said the company was doing everything it could to resolve manufacturing issues as quickly as possible, saying it was still too early to assess the financial impact of the Avandamet and Paxil seizures.
Copyright © 2001 - 2012 Online Lawyer Source
ATTORNEY ADVERTISEMENT—Thank you for your visit. The content published on this website was not written by medical professionals and should not, at any point, be mistaken for medical advice. Furthermore, the information on this site is intended for educational purposes only and should never interfere with a patient/site visitor and his or her healthcare provider. In addition, viewing the content on this website, requesting additional information, or transmitting information through a contact form should never be considered the formation of an attorney-client relationship. The material published on this site is general and may not apply to your specific circumstances. Every case comes with its own set of unique circumstances; past success discussed on this site does not guarantee future performance. Information found on this website should not be used as incentive to act without seeking counsel from a professional. For more information, please read our disclaimer.